Literature DB >> 18166805

A high rate of CLL phenotype lymphocytes in autoimmune hemolytic anemia and immune thrombocytopenic purpura.

Sajjan Mittal, Morgan G Blaylock, Dominic J Culligan, Robert N Barker, Mark A Vickers.   

Abstract

Minor CLL-like clones are found in approximately 3% of healthy individuals. AIHA and ITP are common in CLL and may be causally linked. We investigated the presence of CLL phenotype lymphocytes in 11 cases of primary AIHA, 18 of ITP and 2 of Evans' Syndrome, compared with 26 age-matched healthy controls. A population of 'CLL phenotype' was seen in 6/31 patients compared to 1/26 healthy controls (chi(2)=3.9; p=0.05). Such clones may be important in the pathogenesis of autoimmune blood disorders.

Entities:  

Mesh:

Year:  2008        PMID: 18166805     DOI: 10.3324/haematol.11822

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  14 in total

Review 1.  The ITP syndrome: pathogenic and clinical diversity.

Authors:  Douglas B Cines; James B Bussel; Howard A Liebman; Eline T Luning Prak
Journal:  Blood       Date:  2009-04-24       Impact factor: 22.113

Review 2.  Autoimmune complications in chronic lymphocytic leukaemia (CLL).

Authors:  Clive S Zent; Neil E Kay
Journal:  Best Pract Res Clin Haematol       Date:  2010-03       Impact factor: 3.020

3.  Updated international consensus report on the investigation and management of primary immune thrombocytopenia.

Authors:  Drew Provan; Donald M Arnold; James B Bussel; Beng H Chong; Nichola Cooper; Terry Gernsheimer; Waleed Ghanima; Bertrand Godeau; Tomás José González-López; John Grainger; Ming Hou; Caroline Kruse; Vickie McDonald; Marc Michel; Adrian C Newland; Sue Pavord; Francesco Rodeghiero; Marie Scully; Yoshiaki Tomiyama; Raymond S Wong; Francesco Zaja; David J Kuter
Journal:  Blood Adv       Date:  2019-11-26

4.  Clinical relevance of silent red blood cell autoantibodies.

Authors:  Francesca R Mauro; Fabio Trastulli; Cristiano Alessandri; Guido Valesini; Gianluca Giovannetti; Costantino Riemma; Marika Porrazzo; Sara Pepe; Gioia Colafigli; Maria D Caputo; Maria S De Propris; Anna R Guarini; Gabriella Girelli; Serelina Coluzzi; Robin Foà
Journal:  Haematologica       Date:  2017-09-21       Impact factor: 9.941

Review 5.  Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia.

Authors:  Anders Osterborg; Claes Karlsson; Jeanette Lundin
Journal:  Curr Hematol Malig Rep       Date:  2009-01       Impact factor: 3.952

6.  Clinical and serological autoimmune complications in chronic lymphocytic leukemia.

Authors:  Cengiz Demir; Ömer Ekinci
Journal:  Wien Klin Wochenschr       Date:  2017-05-05       Impact factor: 1.704

7.  Production of the effector cytokine interleukin-17, rather than interferon-γ, is more strongly associated with autoimmune hemolytic anemia.

Authors:  Andrew M Hall; Omar M Zamzami; Natasha Whibley; Daniel P Hampsey; Anne M Haggart; Mark A Vickers; Robert N Barker
Journal:  Haematologica       Date:  2012-03-14       Impact factor: 9.941

8.  IGHV gene rearrangements as outcome predictors for CLL patients: experience of Ukrainian group.

Authors:  I Kryachok; I Abramenko; N Bilous; A Chumak; Z Martina; I Filonenko
Journal:  Med Oncol       Date:  2011-03-04       Impact factor: 3.064

Review 9.  Immune thrombocytopenia.

Authors:  Gaurav Kistangari; Keith R McCrae
Journal:  Hematol Oncol Clin North Am       Date:  2013-06       Impact factor: 3.722

Review 10.  Autoimmunity and lymphomagenesis.

Authors:  Lynn R Goldin; Ola Landgren
Journal:  Int J Cancer       Date:  2009-04-01       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.